CEO William Quinn was paid $4,558,368 in fiscal year 2025, ↑ up 278.8% from fiscal year 2024 (SEC filing 0001193125-26-186923 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$4,558,368 ↑ William Quinn total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
BOLT's next annual pay disclosure, estimated April 28, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| William Quinn | $463,500 | $191,200 | $224,400 | $3,668,768 | $0 | $0 | $10,500 | $4,558,368 |
| President, Chief Executive Officer and Chief Financial Officer | ||||||||
| Grant Yonehiro | 463,500 | 139,100 | 168,300 | 3,236,543 | 0 | 0 | 0 | 4,007,443 |
| Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| William Quinn | $4,558,368 | $1,203,328 | — | ↑ +3,355,040 |
| Grant Yonehiro | 4,007,443 | 948,414 | — | ↑ +3,059,029 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Bolt Biotherapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper BOLT reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses BOLT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named BOLT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| William Quinn | RSU | 2025-10-22 | — | — | 40,000 | — | $218,720 |
| Grant Yonehiro | RSU | 2025-10-22 | — | — | 30,000 | — | 164,040 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| William Quinn | $218,720 | $0 | $0 | 0.0% |
| Grant Yonehiro | 164,040 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| William Quinn | Option | 24,301 | 5.44 | — |
| Grant Yonehiro | Option | 12,151 | 5.44 | — |
| Grant Yonehiro | Option | 4,241 | 5.44 | — |
| Grant Yonehiro | Option | 4,086 | 5.44 | — |
| William Quinn | Option | 4,239 | 5.44 | — |
| William Quinn | RSU | 40,000 | — | 218,720 |
| Grant Yonehiro | RSU | 30,000 | — | 164,040 |
| William Quinn | Option | 347 | 5.44 | — |
| William Quinn | Option | 11,609 | 5.44 | — |
| Grant Yonehiro | Option | 316 | 5.44 | — |
The company's compensation strategy is designed to support and reinforce long-term strategic goals by aligning executive compensation with company performance milestones, specifically related to the development of pre-clinical and clinical assets. The program combines base salary, annual performance bonuses based on company and individual objectives, and long-term equity incentives to attract and retain qualified talent.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon plc (Radford) |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-10 | — | — | — | — | — |
| 2025 | 2025-05-27 | — | — | — | — | — |
| 2024 | 2024-06-12 | — | — | — | — | — |
| 2023 | 2023-06-12 | — | — | — | — | — |
| 2022 | 2022-06-10 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-10 | —a |
| 2025 | 2025-05-27 | —b |
| 2024 | 2024-06-12 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Kathleen LaPorteIndependent · Audit (Chair) | $0 | $0 | $8,592 | — | $0 | $600,249 |
| Brian O’CallaghanIndependent · Board Chair · Audit | 0 | 0 | 7,903 | — | 0 | 448,937 |
| Nicole Onetto, M.DIndependent | 0 | 0 | 10,000 | — | 0 | 310,700 |
| Jakob Dupont, M.DNot independent | 0 | 0 | 110,500 | — | 0 | 191,841 |
| Laura BernerIndependent · Audit | 0 | 0 | 6,563 | — | 0 | 173,672 |
| William P. QuinnEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $0 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $0 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Bolt Biotherapeutics | 2025 | William Quinn | $463,500 | $224,400 | $3,668,768 | $0 | $4,558,368 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, William Quinn | DEF 14A | 2026-04-28 | 0001193125-26-186923 | Section “Executive Compensation”. As printed: 4,558,368. Filing ↗machine: r2 · c25 · span 493167–493176 |
| 2 | Section 01, Grant Yonehiro | DEF 14A | 2026-04-28 | 0001193125-26-186923 | Section “Executive Compensation”. As printed: 4,007,443. Filing ↗machine: r4 · c24 · span 512438–512447 |
| 3 | Section 03, William Quinn RSU | DEF 14A | 2026-04-28 | 0001193125-26-186923 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 611171–611178 |
| 4 | Section 03, Grant Yonehiro RSU | DEF 14A | 2026-04-28 | 0001193125-26-186923 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 712951–712958 |
| 5 | Section 08, Kathleen LaPorte | DEF 14A | 2026-04-28 | 0001193125-26-186923 | Section “Director Compensation”. As printed: 600,249. Filing ↗machine: span 284954–285164 |
| 6 | Section 08, Brian O’Callaghan | DEF 14A | 2026-04-28 | 0001193125-26-186923 | Section “Director Compensation”. As printed: 448,937. Filing ↗machine: span 290968–291178 |
| 7 | Section 08, Nicole Onetto, M.D | DEF 14A | 2026-04-28 | 0001193125-26-186923 | Section “Director Compensation”. As printed: 310,700. Filing ↗machine: span 297128–297338 |
| 8 | Section 08, Jakob Dupont, M.D | DEF 14A | 2026-04-28 | 0001193125-26-186923 | Section “Director Compensation”. As printed: 191,841. Filing ↗machine: span 278947–279157 |
| 9 | Section 08, Laura Berner | DEF 14A | 2026-04-28 | 0001193125-26-186923 | Section “Director Compensation”. As printed: 173,672. Filing ↗machine: span 272791–273001 |
| 10 | Section 08, William P. Quinn | DEF 14A | 2026-04-28 | 0001193125-26-186923 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 11 | Section 06, 2026 vote | Form 8-K | 2026-06-11 | 0001193125-26-267487 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 12 | Section 06, 2025 vote | Form 8-K | 2025-05-28 | 0000950170-25-077880 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 13 | Section 06, 2024 vote | Form 8-K | 2024-06-14 | 0000950170-24-073501 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 14 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 15 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 16 | Section 09b board cost (computed) | Computed | — | — | Cash 0 + equity 0 + all other 0 = 0, summed across the director compensation table rows.machine: formula: Σ = 0 |
| 17 | Bolt Biotherapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-186923 | CEO total compensation as printed in Bolt Biotherapeutics's own proxy. As printed: 4,558,368. Filing ↗machine: r2 · c25 · span 493167–493176 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.